摘要
目的 探讨Graves病 (GD) 1 31 I治疗前后血清可溶性细胞凋亡相关蛋白Fas(sFas)的变化特点及其临床意义。方法 用固相夹心法酶联免疫吸附试验 (ELISA)检测 6 1例GD患者1 31 I治疗前及治疗后不同时期血清sFas含量 ,并与对照组比较。结果 ①GD患者sFas含量为 (174 8± 94 6 )pg ml,明显高于对照组 [(96 6± 10 2 )pg ml,P <0 0 1];与1 31 I治疗前组相比 ,缓解期组sFas含量 [(132 8±34 0 )pg ml]下降 ,但差异无显著性 (P >0 0 5 ) ,临床治愈组sFas含量 [(111 2± 13 2 )pg ml]进一步下降 ,差异有显著性 (P <0 0 5 ) ;甲状腺功能减退 (甲低 )组患者sFas含量 [(10 1 8± 16 3)pg ml]最低 ,差异有显著性 (P <0 0 1)。②sFas与GD患者甲状腺激素 (TH) ,包括TT3、TT4 、FT3和FT4 及促甲状腺激素受体抗体 (TRAb)呈正相关 (r=0 37～ 0 5 9,P <0 0 5 ) ,与年龄、促甲状腺激素 (TSH)、甲状腺球蛋白抗体 (TGAb)和甲状腺微粒体抗体 (TMAb)等无明显相关关系。结论 GD患者体内存在sFas异常表达 ,1 31
Objective To investigate the serum concentration of soluble Fas(sFas) in patients with Graves' disease(GD) before and after 131 I therapy. Methods Serum levels of sFas were measured with enzyme linked immuno sorbent assay (ELISA) in 61 patients before and after 131 I therapy, and the results were compared with that in the control subjects. Results ①The concentration of sFas was significantly higher in GD patients compared with that in the control subjects [(174.8±94.6) pg/ml vs (96.6±10.2) pg/ml, P <0.01)], the serum concentration of sFas decreased after effective 131 I therapy [(132.8±34.0) pg/ml, P >0.05], and was significantly lower in patients with euthyroidism after 131 I therapy [(111.2±13.2) pg/ml, P <0.05], the lowest levels of sFas were observed in patients of hypothyroidism after 131 I therapy [(101.8±16.3) pg/ml, P <0.01]. ②The concentration of serum sFas positively correlated with the titers of antithyrotropin receptor antibody (TRAb) and thyroid hormones (TT 3,TT 4,FT 3, and FT 4, r =0.37～0.59, P <0.05), but not with other clinical parameters (age, TSH, antithyroglobulin antibody titer and antithyromicrosome antibody titer). Conclusion Abnormal serum concentration of sFas can be observed in patients with GD, and regular change of sFas can be found after 131 I therapy of GD.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2003年第2期87-89,共3页
Chinese Journal of Nuclear Medicine
基金
广东省医学科研基金资助项目 (B2 0 0 0 1 4 2 )
